NZ623145B2 - Humanized il-6 and il-6 receptor - Google Patents
Humanized il-6 and il-6 receptor Download PDFInfo
- Publication number
- NZ623145B2 NZ623145B2 NZ623145A NZ62314512A NZ623145B2 NZ 623145 B2 NZ623145 B2 NZ 623145B2 NZ 623145 A NZ623145 A NZ 623145A NZ 62314512 A NZ62314512 A NZ 62314512A NZ 623145 B2 NZ623145 B2 NZ 623145B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- mouse
- human
- gene
- humanized
- mice
- Prior art date
Links
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title description 16
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title description 15
- 241000282414 Homo sapiens Species 0.000 claims abstract description 221
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 108
- 230000001105 regulatory Effects 0.000 claims abstract description 29
- 108091021642 mouse interleukin-6 Proteins 0.000 claims abstract description 13
- 102000004889 Interleukin-6 Human genes 0.000 claims description 105
- 210000004027 cells Anatomy 0.000 claims description 96
- 210000001185 Bone Marrow Anatomy 0.000 claims description 25
- 210000000952 Spleen Anatomy 0.000 claims description 18
- 229920000665 Exon Polymers 0.000 claims description 17
- 206010035485 Plasmacytosis Diseases 0.000 claims description 14
- 210000003593 Megakaryocytes Anatomy 0.000 claims description 13
- 230000001086 cytosolic Effects 0.000 claims description 13
- 210000004436 Chromosomes, Artificial, Bacterial Anatomy 0.000 claims description 10
- 210000001165 Lymph Nodes Anatomy 0.000 claims description 10
- 210000004011 Plasma Cells Anatomy 0.000 claims description 9
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 7
- 206010061989 Glomerulosclerosis Diseases 0.000 claims description 5
- 206010020630 Hypergammaglobulinaemia Diseases 0.000 claims description 4
- 206010038435 Renal failure Diseases 0.000 claims description 4
- 206010041660 Splenomegaly Diseases 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 abstract description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 257
- 229940100601 Interleukin-6 Drugs 0.000 description 82
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 26
- 230000004658 acute-phase response Effects 0.000 description 23
- 210000003719 B-Lymphocytes Anatomy 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 241000699660 Mus musculus Species 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 210000002966 Serum Anatomy 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 230000003393 splenic Effects 0.000 description 13
- 238000004166 bioassay Methods 0.000 description 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 210000004369 Blood Anatomy 0.000 description 11
- 210000004185 Liver Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 210000004556 Brain Anatomy 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 229920002676 Complementary DNA Polymers 0.000 description 8
- 101710006572 ITGAM Proteins 0.000 description 8
- 102100019441 ITGAM Human genes 0.000 description 8
- 210000003734 Kidney Anatomy 0.000 description 8
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 8
- 210000001744 T-Lymphocytes Anatomy 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 101700070228 IFN Proteins 0.000 description 7
- 102100008765 IFNA1 Human genes 0.000 description 7
- 101700066403 IFNA1 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 230000002708 enhancing Effects 0.000 description 7
- 210000004885 white matter Anatomy 0.000 description 7
- 108060001249 CD24 Proteins 0.000 description 6
- 102100000197 CD24 Human genes 0.000 description 6
- 102100002070 FOS Human genes 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 5
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 5
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 206010028289 Muscle atrophy Diseases 0.000 description 5
- 229920001850 Nucleic acid sequence Polymers 0.000 description 5
- 241000779819 Syncarpia glomulifera Species 0.000 description 5
- 229940036248 Turpentine Drugs 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 108090001123 antibodies Proteins 0.000 description 5
- 102000004965 antibodies Human genes 0.000 description 5
- 230000011712 cell development Effects 0.000 description 5
- 230000002025 microglial Effects 0.000 description 5
- 201000000585 muscular atrophy Diseases 0.000 description 5
- 210000002569 neurons Anatomy 0.000 description 5
- 239000001739 pinus spp. Substances 0.000 description 5
- XPVFAGULZMMNRQ-SZURENNPSA-M sodium;(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;N,3-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine;(5Z)-5-(dimethylaminohydrazinylid Chemical compound [Na+].[O-]S(=O)(=O)CCS.CN(C)N\N=C1/N=CN=C1C(N)=O.ClCCNP1(=O)OCCCN1CCCl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XPVFAGULZMMNRQ-SZURENNPSA-M 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- 210000003494 Hepatocytes Anatomy 0.000 description 4
- 229920002459 Intron Polymers 0.000 description 4
- 210000003205 Muscles Anatomy 0.000 description 4
- 102100017511 SPN Human genes 0.000 description 4
- 101710018229 SPN Proteins 0.000 description 4
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001419 dependent Effects 0.000 description 4
- 230000001809 detectable Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 101700063973 lgg-1 Proteins 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000003519 mature B lymphocyte Anatomy 0.000 description 4
- 210000000056 organs Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108010042685 trinitrophenyl keyhole limpet hemocyanin Proteins 0.000 description 4
- 210000002940 B-Lymphoid Precursor Cells Anatomy 0.000 description 3
- 102000004225 Cathepsin B Human genes 0.000 description 3
- 108090000712 Cathepsin B Proteins 0.000 description 3
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 210000004698 Lymphocytes Anatomy 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- 210000003584 Mesangial Cells Anatomy 0.000 description 3
- 206010066453 Mesangioproliferative glomerulonephritis Diseases 0.000 description 3
- 210000000066 Myeloid Cells Anatomy 0.000 description 3
- 102000030951 Phosphotransferases Human genes 0.000 description 3
- 108091000081 Phosphotransferases Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 210000001541 Thymus Gland Anatomy 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- 210000001130 Astrocytes Anatomy 0.000 description 2
- 102000025380 C-Reactive Protein Human genes 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- 108060001038 FOS Proteins 0.000 description 2
- 102000001389 Glial Fibrillary Acidic Protein Human genes 0.000 description 2
- 108010093505 Glial Fibrillary Acidic Protein Proteins 0.000 description 2
- 210000003714 Granulocytes Anatomy 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 206010020718 Hyperplasia Diseases 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 101700057981 PAX5 Proteins 0.000 description 2
- 101700021280 PREB Proteins 0.000 description 2
- DTBNBXWJWCWCIK-UHFFFAOYSA-N Phosphoenolpyruvic acid Natural products OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000011763 Serum Amyloid A Protein Human genes 0.000 description 2
- 108010076895 Serum Amyloid A Protein Proteins 0.000 description 2
- 229920000401 Three prime untranslated region Polymers 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102400000757 Ubiquitin Human genes 0.000 description 2
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 2
- 210000001056 activated astrocyte Anatomy 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 108091006028 chimera Proteins 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 210000002443 helper T lymphocyte Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 230000000284 resting Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002463 transducing Effects 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- AWXGSYPUMWKTBR-UHFFFAOYSA-N 4-carbazol-9-yl-N,N-bis(4-carbazol-9-ylphenyl)aniline Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=C(N(C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=C1 AWXGSYPUMWKTBR-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 108060000679 ATG12 Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 230000037010 Beta Effects 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 210000001217 Buttocks Anatomy 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 101700020617 CD22 Proteins 0.000 description 1
- 102100000189 CD22 Human genes 0.000 description 1
- 210000003967 CLP Anatomy 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 206010061005 Cardiac myxoma Diseases 0.000 description 1
- 208000005024 Castleman Disease Diseases 0.000 description 1
- 102000004172 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N Cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 210000004667 Early pro-B cell Anatomy 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100009142 FANCC Human genes 0.000 description 1
- 101700023762 FANCC Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101700011451 IFNB1 Proteins 0.000 description 1
- 102100015720 IFNB1 Human genes 0.000 description 1
- 101000464841 IL6 Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 210000000014 Large Pre-B cell Anatomy 0.000 description 1
- 241001523179 Lasia <small-headed fly> Species 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 101710033910 MT-I Proteins 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 206010073599 Myeloma cast nephropathy Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 206010051081 Nodular regenerative hyperplasia Diseases 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 210000002997 Osteoclasts Anatomy 0.000 description 1
- 102100018849 PAX5 Human genes 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 230000037289 Plasma half life Effects 0.000 description 1
- 230000037240 Plasma half-life Effects 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 229920001785 Response element Polymers 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
- 102100005486 TCP1 Human genes 0.000 description 1
- 101700078799 TCP1 Proteins 0.000 description 1
- 102100005781 TCTA Human genes 0.000 description 1
- 108060008105 TCTA Proteins 0.000 description 1
- 102100009534 TNF Human genes 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N Trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N Trichloroisocyanuric acid Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 101710039743 acu-6 Proteins 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000037037 animal physiology Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 101710007341 hil-6 Proteins 0.000 description 1
- 102000019518 human IL6 protein Human genes 0.000 description 1
- 229940116886 human Interleukin-6 Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002202 late pro-B cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 108091019810 mouse metallothionein-1 Proteins 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 229920001894 non-coding RNA Polymers 0.000 description 1
- 230000002148 osteoclast Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000000803 paradoxical Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 101700033304 pckG Proteins 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000001817 pituitary Effects 0.000 description 1
- 230000004983 pleiotropic Effects 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000001172 regenerating Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000345 small pre-B cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 101710036128 ywaD Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
Abstract
Disclosed is a genetically modified mouse comprising a replacement at an endogenous mouse IL-6 locus of a mouse gene encoding IL-6 with a human gene encoding human IL-6, wherein the human gene encoding human IL-6 is under control of endogenous mouse regulatory elements at the endogenous mouse IL-6 locus. Also disclosed is a genetically modified mouse, comprising a humanisation of an endogenous mouse IL-6R? gene, wherein the humanisation comprises a replacement of mouse IL-6R? ectodomain-encoding sequence with human IL-6R? ectodomain-encoding sequence at the endogenous mouse IL-6R? locus, and wherein the humanised IL-6R? gene is under control of endogenous mouse regulatory elements. ocus. Also disclosed is a genetically modified mouse, comprising a humanisation of an endogenous mouse IL-6R? gene, wherein the humanisation comprises a replacement of mouse IL-6R? ectodomain-encoding sequence with human IL-6R? ectodomain-encoding sequence at the endogenous mouse IL-6R? locus, and wherein the humanised IL-6R? gene is under control of endogenous mouse regulatory elements.
Description
HUMANIZED IL-6 AND IL-6 RECEPTOR
FIELD OF INVENTION
Non-human animals having a replacement of the endogenous non-human animal
IL-6 and/or IL-6 receptor genes are provided. IL-6 and/or IL-6 receptor genes of the nonhuman
animal are replaced, at the endogenous man loci, with human IL-6 and/or
humanized IL-6 receptor genes comprising human sequence. Non-human animals that
have human IL-6 and/or humanized IL-6 receptor genes, wherein the non-human animals do
not exhibit one or more pathologies that are characteristic of non-human animals transgenic
for human IL-6.
BACKGROUND
Mice transgenic for a human IL-6 gene are known in the art. However, random
insertion of a human IL-6 transgene into the mouse genome results in poorly regulated
expression of the human IL-6 protein, which manifests itself in a variety of pathologies in
such transgenic mice, including, but not limited to, plasmacytosis and glomerulonephritis. As
a result, these mice have limited usefulness.
There is a need for non-human s, e.g., mice and rats, the express human or
humanized IL-6 and/or human or humanized IL-6 receptor. There is a need for such
humanized mice that do not exhibit one or more pathologies exhibited by transgenic hIL-6
mice.
[0003a] In one aspect, the present invention es a genetically modified mouse
comprising a replacement at an endogenous mouse IL-6 locus of a mouse gene encoding
IL-6 with a human gene encoding human IL-6, wherein the human gene encoding human IL-
6 is under control of endogenous mouse tory elements at the endogenous mouse IL-6
locus.
[0003b] In another aspect, the present invention provides a genetically modified mouse,
comprising a humanization of an endogenous mouse IL-6Rα gene, wherein the
humanization comprises a replacement of a mouse IL-6Rα main-encoding sequence
with a human IL-6Rα main-encoding sequence at the endogenous mouse IL-6Rα
locus, and wherein the zed IL-6Rα gene is under l of endogenous mouse
regulatory elements.
[0003c] In another aspect, the present invention provides a method for making a
humanized mouse, comprising replacing a mouse gene sequence encoding mouse IL-6 with
a human gene encoding human IL-6 so that the human IL-6 gene is under control of
endogenous mouse regulatory elements.
[0003d] In another aspect, the present invention provides a method for making a
humanized mouse, comprising replacing all mouse exons encoding ectodomain ces
of mouse IL-6Rα with a human genomic fragment encoding human IL-6Rα main to
form a humanized IL-6Rα gene, wherein the humanized IL-6Rα gene is under control of
endogenous mouse regulatory elements.
[0003e] In another aspect, the present invention provides a genetically modified
mouse comprising a zed IL-6Rα gene comprising a replacement of mouse
ectodomain-encoding sequence with human ectodomain sequence, wherein the zed
IL-6Rα gene comprises a mouse transmembrane sequence and a mouse cytoplasmic
sequence; wherein the mouse further comprises a gene encoding a human IL-6, wherein the
genes encoding human IL-6 and humanized IL-6Rα are under control of endogenous mouse
regulatory elements.
In another aspect, genetically ed man animals are provided that
comprise a replacement at an endogenous IL-6 and/or IL-6 or locus of a gene
encoding an endogenous IL-6 and/or IL-6 receptor with a gene encoding a human or
humanized IL-6 and/or IL-6 receptor. Murine animals are provided that comprise a
ement of an endogenous IL-6 gene, at an endogenous murine IL-6 locus, with a
human IL-6 gene; and/or that comprise a ement of an endogenous IL-6 receptor gene
(or nucleotide sequence encoding an ectodomain thereof) with a human IL-6 receptor gene
(or nucleotide sequence encoding an ectodomain thereof).
In another , genetically modified murine animals are provided that express
a human IL-6 gene under the control of endogenous murine promoter and/or endogenous
murine regulatory elements, from an endogenous murine IL-6 locus.
In another , genetically ed murine animals are provided that express
a human IL-6 receptor gene (or a gene encoding a human ectodomain and murine
embrane and intracellular domains) under the control of endogenous murine
promoter and/or endogenous murine tory elements, from an endogenous
murine lL-6 receptor locus.
In one aspect, a genetically modified animal (e.g., a murine , e.g., a
mouse or rat) is provided that expresses a human lL-6 protein, wherein the non-
human animal does not exhibit a pathology selected from plasmacytosis,
glomerulonephritis, glomerulosclerosis, mesangio-proliferative glomerulonephritis,
intestinal lymphoma, kidney lymphoma, megaly, lymph node enlargement,
liver enlargement, megakaryocytes in bone marrow, compacted abnormal plasma
cells, infiltration of plasma cells into lung or liver or kidney, mesangial cell
proliferation in kidney, cerebral overexpression of lL-6, ramified microglial cells in
white matter, reactive astrocytosis in brain, kidney failure, elevated megakaryocytes
in spleen, muscle wasting (e.g., gastrocnemius muscle wasting), elevated muscle
cathepsins B and B+L (e.g., around 20-fold and 6-fold), and a combination f.
In one embodiment, the man animal ses a normal B cell
population. In one embodiment, the normal B cell population is approximately the
same in number and immunophenotype as a wild-type animal, e.g., a wild-type
mouse.
In one embodiment, the non-human animal is murine (e.g., a mouse or rat)
and expresses human lL-6 (hlL-6) in serum at a level below about 800 pg/mL, below
about 700, 600, 500, 400, 300, or 200 pg/mL. In a specific embodiment, the murine
animal expresses hlL-6 in serum at a level of about 50 to about no more than 200
pg/mL, in another embodiment about 75-125 pg/mL, in another embodiment at about
100 pg/mL.
In one aspect, a non-human animal is ed that expresses hlL-6 and/or
hlL-6R, wherein the non-human animal expresses hlL-6 and/or hlL-6R from an
endogenous non-human lL-6 locus and/or an endogenous non-human hlL-6R locus.
In a specific ment, the non-human animal is murine (e.g., mouse or rat).
In one , a genetically modified mouse is provided that expresses hlL-6
from an endogenous mouse lL-6 locus, n the endogenous mouse lL-6 gene
has been replaced with a hlL-6 gene.
In one embodiment, the mouse comprises a cell that expresses an lL-6
receptor (IL-6R) that comprises a human ectodomain on the surface of the cell. In
one embodiment, the cell is a lymphocyte. In one ment, the lymphocyte is a
B cell.
In one embodiment, about 6.8 kb at the endogenous mouse lL-6 locus,
including exons 1 through 5 and a 3’ untranslated sequence, is deleted and replaced
with about 4.8 kb of human lL-6 gene sequence comprising exons 1 through 5 of the
human lL-6 gene. In a specific embodiment, the human lL-6 gene ses exons
1 through 5 of the human lL-6 gene of human BAC CTD-2369M23.
In one aspect, a genetically modified mouse is provided that expresses lL-6
from a human lL-6 gene, wherein the mouse expresses human lL-6 in its serum.
In one embodiment, the mouse serum exhibits a serum concentration of
human lL-6 of about 25 to about 300 pg/mL, 50 to about 250 pg/mL, 75 to about 200
pg/mL, or 100 to about 150 pg/mL. In a specific embodiment, the level of human lL-6
in the serum of the mouse is about 100 pg/mL.
In one ment, the level of a pan B cell-specific marker in bone marrow
of the mouse is about the same as that of a ype mouse. In one embodiment,
the level of a pan B cell-specific marker in spleen is about the same as that of a wild-
type mouse. In one embodiment, the pan B cell-specific marker is selected from
B220, CD19, CD20, CD22, CD79a, CD79b, L26, and Pax-5 (BSAP).
In one , a genetically modified mouse is provided that expresses hlL6,
wherein the mouse does not exhibit a feature selected from plasmacytosis,
splenomegaly, lymph node enlargement, compacted abnormal plasma cells, and a
combination thereof.
In one embodiment, the mouse comprises a spleen that is about the same
weight (per body weight) as a wild-type mouse. In one embodiment, the lymph
nodes of the mouse are about the same weight (per body ) as a wild-type
mouse. In one embodiment, plasma cells of the mouse do not exhibit plasmocytosis
characteristic of mice that overexpress human lL-6.
In one embodiment, the mouse does not t glomerulonephritis.
In one embodiment, the mouse exhibits a mesangial cell level comparable to
a wild-type mouse.
In one aspect, a genetically modified mouse is provided that expresses hlL6
from an endogenous mouse lL-6 locus, wherein the endogenous mouse lL-6 gene
has been replaced with a hlL-6 gene, wherein the mouse does not exhibit a feature
selected from a logically detectable neuropathology, a reactive astrocytosis,
and a combination thereof. In one ment, the mouse ses a brain that is
morphologically indistinct from a ype mouse brain. In one embodiment, the
mouse comprises brain tissue that exhibits a level of reactive astrocytosis that is no
higher than that of a wild-type mouse.
In one embodiment, the mouse does not express human lL-6 in neurons. In
one embodiment, the mouse comprises activated astrocyte levels that are
comparable to activated astrocyte levels in a wild-type mouse.
In one embodiment, the mouse comprises ramified microglial cells in its white
matter, wherein the ramified lial cells are present in an amount equivalent to
an amount of ramified microglial cells in a wild-type mouse.
In one embodiment, the mouse does not t a reactive atrocytosis. In one
ment, the white matter of the mouse is morphologically indistinct from the
white matter of a wild-type mouse. In one embodiment, the white matter of the
mouse is histologically indistinct from a wild-type mouse white matter with t to
hemical staining of reactive astrocytes.
In one embodiment, the mouse comprises a brain that is morphologically
inct from a wild-type mouse brain. In one embodiment, the mouse comprises
brain tissue that exhibits a level of reactive astrocytosis that is no higher than that of
a wild-type mouse.
In one aspect, a genetically modified mouse is provided that expresses hlL6
from an endogenous mouse lL-6 locus, wherein the endogenous mouse lL-6 gene
has been ed with a hlL-6 gene, wherein the mouse does not exhibit a feature
selected from a life span shortened by about 50% or more, kidney failure,
hypergammaglobulinemia, elevated megakaryocytes in spleen, elevated
megakaryocytes in bone marrow, plasmacytosis of , plasmacytosis of thymus,
plasmacytosis of lymph nodes, glomerulonephritis, glomerulosclerosis, and a
combination thereof.
In one embodiment, the mice have a life span that exceeds 20 weeks. In one
embodiment, the mice have a life span that exceeds 30 weeks, 40 weeks, or 50
weeks. In one embodiment, the mice exhibit a life span about equal to that of a wild-
type mouse of the same strain.
In one ment, the mice exhibit a level of megakaryocytes in spleen that
is no more than about the splenic megakaryocyte level of a wild-type mouse
In one embodiment, the mice comprise lymphoid organs that are ially
devoid of abnormal and compactly arranged plasmacytoid cells.
In one embodiment, the mice exhibit gamma in serum levels equivalent
to gamma globulin serum levels in wild-type mice. In one embodiment, the levels of
(11- and B-globulin in serum of the mice are equivalent to (11- and B-globulin serum
levels of wild-type mice of the same strain.
In one aspect, a genetically modified mouse is provided that expresses
human lL-6 from an endogenous mouse lL-6 locus, wherein the endogenous mouse
lL-6 gene has been replaced with a hlL-6 gene, wherein the mouse does not exhibit
a feature selected from muscle wasting, an elevated cathepsin B level as compared
with a wild-type mouse of the same strain, an elevated cathepsin A+B level as
compared with a wild-type mouse of the same strain, an increased liver weight as
compared with a wild-type mouse of the same strain, and a combination f.
In one embodiment, the weight of the liver of the mouse is about 800-900 mg
at 12 weeks.
In one embodiment, the mouse exhibits a cathepsin B level throughout its life
span that is no more than about the level observed in a wild-type mouse. In one
embodiment, the mouse exhibits a cathepsin A+B level throughout its life span that is
no more than about the level observed in a wild-type mouse.
In one ment, the mouse as an adult exhibits a gastrocnemus muscle
weight that is within about 10% of the weight of a wild-type mouse of the same strain.
In one embodiment, the mouse as an adult ts a gastrocnemus muscle weight
that is about the same as that of a wild-type mouse.
In one aspect a mouse is provided that ses a nucleotide sequence
encoding a human lL-6 protein, wherein the nucleotide sequence encoding the
human lL-6 protein replaces in whole or in part an endogenous nucleotide sequence
encoding and endogenous mouse lL-6 protein.
In one aspect, a mouse is provided that comprises a replacement at an
endogenous mouse lL-6 receptor locus of mouse lL-6Ra ectodomain with an
ectodomain sequence of a human lL-6Rq to form a chimeric human/mouse lL-6Ra
gene.
In one ment, the chimeric lL-6Ra gene is under the control of a mouse
promoter and/or mouse regulatory elements at the endogenous mouse lL-6Rq locus.
In one embodiment, about 35.4 kb of mouse lL-6Rq ectodomain-encoding
sequence is replaced with about 45.5 kb of human lL-6R ectodomain-encoding
In one embodiment, the human lL-6R ectodomain-encoding sequence
encompasses the first (ATG) codon in exon 1 through exon 8.
In one embodiment, the mouse lL-6Rq ce that is replaced includes a
uous sequence that encompasses exons 1 h 8. In a ic
embodiment, exons 1 through 8 and a n of intron 8 is deleted.
In one , a genetically ed mouse is provided, comprising a
replacement at an endogenous mouse lL-6 locus of a mouse gene encoding lL-6
with a human gene encoding human lL-6, wherein the human gene encoding human
lL-6 is under control of endogenous mouse tory elements at the endogenous
mouse lL-6 locus.
In one embodiment, the human gene encoding human lL-6 is a human lL-6
gene of BAC ID CTD-2369M23.
In one embodiment, the mouse expresses a mouse lL-6Rq. In one
embodiment, the mouse expresses a human lL-6Rq. In one embodiment, the
humanized lL-6Ror comprises a human main. In one embodiment, the
humanized lL-6Rq comprises a mouse transmembrane domain and a mouse
cytoplasmic domain. In one embodiment, the mouse expresses a humanized lL-6Rq
that comprises a humanization of ectodomain but not transmembrane and/or
cytosolic domain.
In one embodiment, the mouse does not exhibit a feature selected from
plasmocytosis, glomerulosclerosis, glomerulonephritis, kidney e,
hypergammaglobulinemia, ed ryocytes in spleen, elevated
megakaryocytes in bone marrow, splenomegaly, lymph node enlargement,
compacted abnormal plasma cells, and a combination thereof.
In one aspect, a genetically modified mouse is provided, comprising a
humanization of an endogenous mouse lL-6Ror gene, wherein the zation
comprises a replacement of mouse lL-6Rq ectodomain-encoding sequence with
human lL-6Rq ectodomain-encoding sequence at the endogenous mouse lL-6Rq
locus.
In one ment, a contiguous mouse sequence comprising mouse exons
1 h 8 is replaced with a contiguous genomic fragment of human lL-6Ror
sequence encoding a human lL-6Rq ectodomain. In one embodiment, the
contiguous genomic fragment of human lL-6Rq sequence encoding the ectodomain
is from BAC CTD-2192J23.
In one embodiment, the mouse further comprises a humanized lL-6 gene. In
one embodiment, the mouse comprises a replacement at an endogenous mouse lL-6
locus of a mouse lL-6 gene with a human lL-6 gene. In one embodiment, the
humanized lL-6 gene is under control of endogenous mouse regulatory elements.
In one aspect, a method is provided for making a humanized mouse,
sing replacing a mouse gene sequence encoding mouse lL-6 with a human
gene encoding human lL-6.
In one embodiment, the replacement is at an nous mouse lL-6 locus,
and the human gene encoding human lL-6 is operably linked to endogenous mouse
tory sequences.
In one aspect, a method for making a humanized mouse is provided,
comprising replacing mouse exons ng ectodomain sequences of mouse |L-
6Rq with a human genomic fragment encoding ectodomain sequences of human |L-
6Rq to form a humanized lL-6Rq gene.
In one embodiment, the replacement is at an endogenous mouse lL-6Rq
locus, and the humanized lL-6Rq gene is ly linked to nous mouse
tory sequences.
In one aspect, a genetically ed mouse is provided, comprising a
humanized lL-6Rq gene comprising a ement of mouse ectodomain-encoding
sequence with human ectodomain sequence, wherein the humanized lL-6Rq gene
ses a mouse transmembrane sequence and a mouse cytoplasmic sequence;
wherein the mouse further comprises a gene encoding a human lL-6, wherein the
gene encoding a human lL-6 is under control of endogenous mouse lL-6 regulatory
elements.
In one embodiment, the mouse is incapable of expressing a fully mouse lL-
6Rq and incapable of expressing a mouse lL-6.
In various s, the genetically modified mice described herein comprise
the genetic modifications in their germline.
In one aspect, a tissue, cell, or membrane fragment from a mouse as
described herein is provided.
In one embodiment, the tissue or cell is from a mouse that expresses a
human lL-6 protein, but that does not express a mouse lL-6 protein. In one
embodiment, the tissue or cell is from a mouse that expresses a humanized lL-6Rq
n, but not a mouse lL-6Rq protein. In one embodiment, the humanized lL-6Rq
protein comprises a human ectodomain and a mouse transmembrane domain and a
mouse cytosolic domain. In one embodiment, the tissue or cell is from a mouse that
expresses a human lL-6, a humanized lL-6Rq, and that does not express a mouse
lL-6 and does not express an lL-6Rq that comprises a mouse ectodomain.
In one aspect, an ex vivo complex of a mouse cell bearing a humanized lL-
6Rq (human ectodomain and mouse transmembrane and mouse cytoplasmic
domain) and a human lL-6 is provided.
In one , a mouse embryo comprising a genetic modification as
described herein is provided.
In one aspect, a mouse host embryo is provided that comprises a donor cell
that comprises a genetic modification as described herein.
In one , a pluripotent or totipotent man animal cell comprising a
genetic modification as described herein is provided. In one embodiment, the cell is
a murine cell. In one embodiment, the cell is an E8 cell.
In one aspect, a mouse egg is ed, wherein the mouse egg comprises
an ectopic mouse chromosome, n the c mouse chromosome comprises
a genetic cation as described herein.
In one aspect, the mouse, embryo, egg, or cell that is genetically modified to
comprise a human lL-6 gene or human or humanized lL-6Ra gene is of a mouse that
is of a C57BL strain selected from C57BL/A, C57BL/An, C57BL/GrFa,
C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6NJ, C57BL/10,
C57BL/10808n, C57BL/10Cr, and C57BL/Ola. In another embodiment, the mouse is
a 129 strain selected from the group consisting of a strain that is 129P1, 129P2,
129P3, 129X1, 12981 (e.g., 8V, 12981/8vlm), 12982, 12984, 12985,
12989/8vaH, 12986 (129/8vaTac), 12987, 12988, 129T1, 129T2 (see, e.g.,
Festing et al. (1999) d nomenclature for strain 129 mice, Mammalian Genome
:836, see also, Auerbach et al (2000) Establishment and Chimera Analysis of
129/8va- and C57BL/6-Derived Mouse Embryonic Stem Cell Lines). In a specific
embodiment, the genetically modified mouse is a mix of an aforementioned 129
strain and an aforementioned C57BL/6 strain. In another specific embodiment, the
mouse is a mix of aforementioned 129 strains, or a mix of aforementioned BL/6
strains. In a specific embodiment, the 129 strain of the mix is a 12986
(129/8vaTac) . In another embodiment, the mouse is a BALB strain, e.g.,
BALB/c strain. In yet another embodiment, the mouse is a mix of a BALB strain and
another aforementioned strain. In one embodiment, the mouse is 8wiss or 8wiss
Webster mouse.
Each of the aspects and embodiments described herein are capable of being
used together, unless excluded either explicitly or y from the context of the
embodiment or aspect.
BRIEF PTION OF THE GS
provides an illustration, not to scale, of the human (top) and mouse
(bottom) lL-6 genomic loci. Exons I, II, III, IV, and V (in both human and mouse) are
indicated by closed boxes to the right in the figure. 8elected ve regulatory
regions are indicated by open boxes to the left in the figure.
shows acute phase response (mSAA level) in the presence or
absence of turpentine in wild-type mice, humanized ectodomain IL-6R mice, and
mice with humanized IL-6 and IL-6R genes.
shows turpentine-dependent acute phase response (8AA) in wild-type
mice the e or presence of anti-mouse IL-6R antibody (left); and turpentine-
dependent acute phase response in humanized L-6R mice in the absence or
present of anti-human IL-6R antibody (right).
shows FACS analysis for splenic B cells of wild-type and humanized
IL-6 mice; pan B cell marker.
shows FACS analysis for splenic T cells of wild-type an humanized IL-
6 mice; T helper cells and cytotoxic T cells.
shows FACS analysis for c cells of wild-type and humanized IL-6
mice; Ly6G/C(Gr1).
shows FACS analysis for splenic cells of wild-type and humanized IL-6
mice; NK cells and granulocytes (Ly6Ghi+/CD11bhi+).
shows FACS analysis for blood B cells of wild-type and humanized IL-
6 mice; pan B cell marker.
shows FACS analysis for blood T cells of wild-type and humanized IL-
6 mice; T helper cells and cytotoxic T cells.
shows FACS analysis for blood myeloid cells of wild-type and
humanized IL-6 mice; Gr1+ cells.
shows FACS analysis for blood myeloid cells of wild-type and
humanized IL-6 mice; CD11b vs. Ly6G/C(Gr1).
shows FACS analysis for blood d cells of wild-type and
humanized IL-6 mice; DX5 vs CD11b cells.
shows FACS is of bone marrow IgM/CD24/B220 for wild-type
and zed IL-6 mice. Top: normal progression in bone marrow. Bottom: FACS
analysis for wild-type, hlL-6 heterozygotes, and hlL-6 homozygotes (IgM staining).
shows FACS analysis of bone marrow IgM/CD24/B220 for ype
and humanized IL-6 mice. Top: normal progression in bone marrow. Bottom: FACS
analysis for ype, hlL-6 heterozygotes, and hlL-6 homozygotes (CD24 staining).
shows FACS analysis of bone marrow CD43 and B220 for wild-type
and zed IL-6 mice. Top: normal progression in bone marrow. Bottom: FACS
analysis for wild-type, hlL-6 heterozygotes, and hlL-6 homozygotes (CD43 staining).
DETAILED DESCRIPTION
lL-6 and lL-6R
The |L-6 or (IL-6R) was long terized as a receptor for a B cell
atory factor (BSF-2, or B cell Stimulatory Factor 2; also, BCDF, or B Cell
Differentiation Factor) responsible for inducing B cells to synthesize immunoglobulin
(Yamasaki et al. (1988) Cloning and Expression of the Human Interleukin-6(BSF-
2/lFNB 2) Receptor, Science 241 :825-828). lL-6 was first described as interferon-[52
as the result of its discovery during a search for a virally-induced protein termed
interfereon-B, by treating human fibroblasts with dsRNA poly(|)poly(C) to induce an
anti-viral response (Weissenbach et al. (1980) Two interferon mRNAs in human
fibroblasts: In vitro translation and Escherichia coli cloning studies, Proc. Natl Acad.
Sci. USA 77(12):?152-7156; Keller et al. (1996) Molecular and Cellular Biology of
Interleukin-6 and Its Receptor, Frontiers in ence 1:d340-357).
The human cDNA encodes a 468 amino acid protein having a 19-mer signal
sequence and a cytoplasmic domain of about 82 amino acids that lacks a tyrosine
kinase domain (see, Id.). The N-terminal (ectodomain) of the protein has an lg
superfamily domain of about 90 amino acids, a 250-amino acid domain between the
Ig superfamily domain and the membrane, a transmembrane span of about 28 amino
acids (see, Id.). The ectodomain of the receptor binds its ligand lL-6, which triggers
association with gp130 in the membrane and it is this complex that conducts signal
transduction; the cytoplasmic domain reportedly does not transduce signal (Taga et
al. (1989) Interleukin-6 Triggers the Association of Its Receptor with a Possible
Signal Transducer, gp130, Cell 58:573-581). Indeed, a soluble form of lL-6R lacking
a cytoplasmic domain can associate with |L-6 and bind gp130 on the e of a cell
and effectively transduce signal (Id.).
The homology of hlL-6R and mlL-6R at the protein level is only about 54%;
the transmembrane domain has a homology of about 79%, whereas the cytoplasmic
domain has a homology of about 54% (Sugito et al. (1990)).
The natural ligand for the |L-6R, |L-6, was first isolated from es of HTLV-
1-transformed T cells (see, Hirano et al. (1985) cation to homogeneity and
characterization of human B cell differentiation factor (BCDF or BSFp-2), Proc. Natl.
Acad. Sci. USA 82:5490-5494). A human cDNA for the |L-6 gene was cloned at
least twice, once as BSF-2 (see, Hirano et al. (1086) mentary DNA fro a
novel human interleukin (BSF-2) that induces B lymphocytes to produce
immunoglobulin, Nature 324:73-76) and once as lFNB 2 (see, stein et al. (1986)
ure and expression of cDNA and genes for human eron-beta-2, a distinct
species inducible by growth-stimulatory cytokines, EMBO 5:2529-2537), although it
has since been demonstrated that recombinant human lL-6 ts no detectable
IFN activity.
Human lL-6 is a 184-amino acid protein that exhibits only about 42%
homology with mouse lL-6, although the genomic organization of the human and
mouse genes are basically the same, and the promoter s of the human and
mouse genes share a 400-bp stretch that is highly conserved (see, Tanabe et al.
(1988) Genomic Structure of the Murine lL-6 Gene: High Degree Conservation of
Potential tory Sequences between Mouse and Human, J. lmmunol.
141(11):3875-3881).
The human lL-6 gene is about 5 kb (Yasukawa et al. (1987) Structure and
expression of human B cell stimulatory factor-2 (BSC-2/lL-6) gene, EMBO J.
2939-2945), whereas the mouse lL-6 gene is about 7 kb (Tanabe et al. (1988)
Genomic Structure of the Murine lL-6 Gene: High Degree Conservation of Potential
Regulatory Sequences between Mouse and Human, J. lmmunol. 141(11):3875-
3881). The mouse and human lL-6 genes reportedly share highly conserved 5'-
flanking sequence important to regulation. A schematic diagram of the human and
mouse lL-6 genomic loci is shown in (not to scale). Exons I, II, III, IV, and V
(in both human and mouse) are indicated by closed boxes to the right in the figure.
Selected putative regulatory regions are indicated by open boxes to the left in the
figure. The putative regulatory s for humans are, from left to right, a
glucocorticoid t from -557 to -552; an IFN enhancer core sequence from -472
to -468; a glucocorticoid element from -466 to -461; an AT-rich region from -395 to -
334, a consensus AP-1 binding site from -383 to -277; an IFN enhancer core
ce from -253 to -248; a containing motif from -205 to -192; a c-fos
SRE homology sequence from -169 to -82 containing an IFN enhancer core
sequence, a cAMP-response t, a GGAAA motif, a CCAAT box, and a GC-rich
; and AP-1 binding site from -61 to -55; and a CCAAT box from -34 to -30. The
putative regulatory regions for mouse are, from left to right, a GC rich region from -
553 to -536, a orticoid t from -521 to -516 and from -500 to -495; a Z-
DNA stretch from -447 to -396; an AP-1 binding site overlapping an IFN enhancer
core sequence from -277 to -288, a GGAAA motif overlapping an IFN enhancer core
sequence from -210 to -195; a c-fos SRE homology region from -171 to -82
containing a cAMP response element, a GGAAA motif overlapping an IFN enhancer
core sequence, and a GC-rich region; and, an AP-1 binding site from -61 to -55.
Mouse codons l-V have lengths 19, 185, 114, 150, and 165, respectively. Mouse
intron lengths are: l-ll, 162 bp; ll-lll, 1253 bp; lll-IV, 2981 bp; |V-V, 1281 bp. Human
codons l-V have lengths 19, 191, 114, 147, and 165. Human intron lengths are l-ll,
154; ll-lll, 1047; lll-lV, 706; lV-V, 1737. Genomic organization data are from Tanabe
et al. (1988), and Yasukawa et al. (1987) Structure and expression of human B cell
stimulatory factor-2 (BSF-2/lL-6) gene, EMBO J. 9(10):2939-2945.
It might be reasonable to presume that the mouse and human |L-6 genes
appear to be similarly regulated based on the similarity of their 5'-flanking sequence.
A variety cell types exhibit enhanced |L-6 expression in response to |L-1, TNF,
PDGF, IFNB, serum, poly(l)poly(C), and cycloheximide (see, Tanabe etal. (1988).
lL-6 in humans mediates the acute phase response, hematopoiesis, B cell
differentiation, T cell activation, growth and/or differentiation and/or activation of a
variety of cell types (e.g., hepatocytes, lasts, elial cells, neurons,
pituitary cells, lymphomas, myelomas, breast carcinomas, NK cells, macrophages,
osteoclasts, etc.) (reviewed in, e.g., Heinrich et al. (1990), Kishimoto et al. (1989),
and Keller et al. (1996); Sugita et al. (1990) Functional Murine Interleukin Receptor
with lntracisternal A Particle Gene Product at its Cytoplasmic Domain, J. Exp. Med.
171:2001-2009).
In practice, however, mice transgenic for human lL-6 exhibit a panoply of
ntial and debilitating ogies, reflecting a significant pleiotropy of the |L-6
gene. enic mice comprising a 6.6-kb fragment containing the human |L-6
gene and a p er (Eu) produce high concentrations of hlL-6 and extremely
high lgG1 levels (120- to 400-fold over wild-type mice), reflecting an |L-6
deregulation that is accompanied by plasmacytosis, mesangio-proliferative
glomerulonephritis, and high bone marrow megakaryocyte levels (Suematsu et al.
(1989) lgG1 plasmacytosis in interleukin 6 transgenic mice, Proc. Natl Acad. Sci.
USA 86:7547-7551). Aberrant regulation of |L-6 and/or |L-6R is associated with
myelomas, plastocytomas, toid tis, Castleman's disease, mesangial
proliferative ulonephritis, cardiac myxoma, plams cell neoplasias, psoriasis,
and other disorders (see, Kishimoto, T. (1989) The Biology of eukin-6, Blood
74(1):1-10; Sugita et al. (1990); also, Hirano et al. (1990) Biological and al
aspects of interleukin 6, Immunology Today 11(12):443-449)). |L-6 is also implicated
in sustaining levels of intra-prostatic androgens during androgen deprivation
ent of prostate cancer patients by a paracrine and/or autocrine ism,
potentially providing castration-resistant prostate tumor growth (Chun et al. (2009)
eukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells, Clin. Cancer
Res. 15:4815-4822).
The human protein is encoded as a 212 amino acid protein, in mature form a
184 amino acid protein following cleavage of a 28 amino acid signal sequence. It
contains two osylation and two osylation sites, and human |L-6 is
phosphorylated in some cells. The mouse protein is encoded as a 211 amino acid
protein, in mature form a 187 amino acid protein following cleavage of a 23 amino
acid signal sequence. O-glycosylation sites are present, but not N-glycosylation
sites. (See reviews on lL-6, e.g., Heinrich et al. (1990) Interleukin-6 and the acute
phase response, Biochem. J. 1-636.)
lL-6 on is pleiotropic. The lL-6 receptor is found on activated B cells but
reportedly not on resting B cells. In contrast, lL-6R is found on resting T cells and
can reportedly e T cell differentiation, activation, and proliferation, including
the differentiation of T cells into cytotoxic T lymphocytes in the presence of |L-2.
Humanized lL-6/lL-6R Ectodomain Mice and lLMediated Acute Phase
Response
In humans, lL-6 induces the acute phase response. Early studies with human
hepatocytes established that lL-6 induces acute phase proteins such as, e.g., C-
reactive protein (CRP) and serum amyloid A (SAA) in a dose-dependent and time-
dependent manner (reviewed in Heinrich et al. (1990) Interleukin-6 and the acute
phase response, Biochem. J. 265:621-636). Non-human animals, e.g., mice or rats,
sing humanized lL-6 and lL-6R genes are therefore useful systems for
measuring the acute phase response mediated by human lL-6. Such animals are
also useful for ining whether a nce induces an lLmediated acute
phase response, by ng a humanized lL-6/lL-6R animal as described herein to
the substance, and measuring a level of one or more acute phase response proteins
(or RNAs). In one embodiment, the humanized animal is exposed to the substance
in the presence of an antagonist of a human lL-6R, and a level of one or more acute
phase response proteins (or RNAs) is measured, wherein a reduction in a level of an
acute phase response protein (or RNA) in the presence of the human lL-6R
antagonist indicates a human lL-6R-mediated acute phase response.
Human lL-6 can bind both human lL-6R and mouse lL-6R; mouse lL-6 binds
mouse lL-6R but not human lL-6R (no binding of mlL-6 to hlL-6R detectable,
whereas hlL-6 can compete with mlL-6 for binding mlL-6R; Coulie et al. (1989) High-
and finity ors for murine interleukin 6. Distinct bution on B and T
cells, Eur. J. l. 19:2107-211); see also, e.g., Peters etal. (1996) The
Function of the Soluble Interleukin 6 (IL-6) Receptor In Vivo: Sensitization of Human
Soluble IL-6 Receptor Transgenic Mice Towards IL-6 and Prolongation of the Plasma
Half-life of IL-6, J. Exp. Med. 183:1399-1406). Thus, human cells that bear hlL-6R in
a mouse (e.g., in a xenogenic transplant) cannot rely on endogenous mlL-6 to carry
out ILmediated functions, including but not limited to the role of IL-6 blood cell or
lymphocyte development (e.g., hematopoiesis, B cell activation, T cell activation,
etc.)
In a mixed in vivo system sing a wild-type mouse IL-6 gene and a
human IL-6R gene (but no mouse IL-6R gene), an acute phase response r is
not expected to induce detectable levels of acute phase proteins that would indicate
an acute phase response. However, a humanized mouse as described herein,
comprising a humanized IL-6 gene and an IL-6R gene comprising a humanized
ectodomain sequence will respond to an acute phase response inducer and exhibit
acute phase response proteins in serum. Mice wild-type for L-6R tested for
acute phase proteins in the presence or absence of the acute phase inducer
turpentine showed a turpentine-dependent increase in acute phase proteins. Mice
with humanized IL-6 gene, but not IL-6R, showed no acute phase se in the
presence of turpentine. But mice bearing both a human IL-6 gene and an IL-6R
gene with a humanized ectodomain exhibited a strong acute phase response (. The ediated acute phase response was IL-6 dependent in both wild-type
mice ( top) and in humanized IL-6/IL-6R ectodomain mice ( bottom), as
evidenced by the ability of the appropriate L-6R antibody to te the acute
phase response at a sufficiently high antibody dose. Thus, a double humanization of
IL-6 and IL-6R recapitulates the wild-type ILmediated acute phase response with
t to serum acute phase proteins.
cally Modified Mice
Genetically modified mice are provided that express a human IL-6 and/or a
humanized IL-6 receptorfrom endogenous mouse loci, wherein the endogenous
mouse IL-6 gene and/or the endogenous mouse IL-6 receptor gene have been
replaced with a human IL-6 gene and/or a human sequence comprising a sequence
that encodes an ectodomain of a human IL-6 receptor. The genetically modified
mice express the human IL-6 and/or humanized IL-6 receptor from zed
endogenous loci that are under control of mouse promoters and/or mouse regulatory
elements. The replacement(s) at the endogenous mouse loci provide non-human
animals that express human IL-6 and a zed IL-6 or in a manner that
does not result in the panoply of ntial pathologies observed in IL-6 transgenic
mice known in the art.
Transgenic mice that express human lL-6 are known in the art. However,
they generally suffer from significant pathologies that ly limit their usefulness.
Humanized mice as described herein express a human lL-6 and/or humanized lL-6
receptor under the control of endogenous mouse regulatory elements at endogenous
mouse lL-6 and lL-6Rq loci. These mice, in contrast, exhibit expression patterns
with respect to these genes that are different from transgenic mice known in the art.
Replacement of man genes in a non-human animal with homologous
or orthologous human genes or human sequences, at the endogenous non-human
locus and under l of nous promoters and/or regulatory elements, can
result in a non-human animal with qualities and characteristics that may be
substantially different from a typical knockout-plus—transgene animal. In the typical
knockout-plus-transgene animal, an endogenous locus is removed or d and
a fully human transgene is inserted into the animal's genome and presumably
integrates at random into the genome. Typically, the location of the ated
transgene is unknown; expression of the human protein is measured by transcription
of the human gene and/or protein assay and/or functional assay. Inclusion in the
human transgene of upstream and/or downstream human sequences are apparently
presumed to be sufficient to provide suitable support for expression and/or tion
of the transgene no matter where in the 's genome the transgene winds up.
But in many cases the transgene with human regulatory elements expresses in a
manner that is unphysiological or othenNise unsatisfactory, and can be actually
detrimental to the animal. In contrast, the inventors demonstrate that a replacement
with human sequence at an endogenous locus under control of endogenous
regulatory elements provides a physiologically riate expression pattern and
level that s in a useful humanized animal whose logy with respect to the
replaced gene are meaningful and appropriate and context of the humanized
animal's physiology.
ized mouse eggs injected with a construct having the MHC class I
promoter H2 and a B-globin intron driving expression of a 695-bp mouse lL-6 gene
reportedly produce mice that constitutively express mouse lL-6 at relatively high
levels (as compared with wild-type mice) (see, Woodrofe et al. (1992) Long-Term
Consequences of Interleukin-6 Overexpression in enic Mice, DNA and Cell
Biology 11(8):587-592). But these mice are prone to develop lymphomas ated
with the intestines, lymph nodes, and kidney, as well as splenic amyloid deposits.
They also exhibit abnormal B cell maturation (see, Woodrofe et al., ld.), so that
studies of B cell on are compromised. In contrast, mice as described herein
that comprise a replacement of the mouse lL-6 gene with a human lL-6 gene at the
mouse lL-6 locus are not prone to develop these lymphomas, and the mice exhibit
apparently normal B cell populations.
Mice (C57BL/6) transgenic for hlL-6 due to a random insertion of a 6.6-kb
(BamHl-Pvu ll fragment) length of human DNA containing the hlL-6 gene coupled
with an lgM enhancer have been reported (see, Suematsu et al. (1989) lgG1
cytosis in interleukin 6 transgenic mice, Proc. Natl. Acad. Sci. USA 86:7547-
7551). The mice express hlL-6 at between 800 pg/mL and 20,000 pg/mL in serum,
where wild-type mice typically express only about 100 pg/mL lL-6. The mice exhibit
an increase in serum lg (120 to 400-fold over wild-type mice) and a decrease in
albumin as they age. The mice suffer from a massive plasmacytosis, exhibit
megaly and lymph node enlargement, as well as exhibiting plasma cells and
sed megakaryocytes in bone marrow. Upon inspection, what appear to be
enlarged lymph nodes are instead massed of compacted al plasma cells.
Both spleen and thymus exhibit massive proliferation of plasma cells, which also
infiltrate portions of the lung, liver, and kidney. Kidney in these mice also exhibits |L-
ulated mesangial cell proliferation typical of mesangio-proliferative
glomerulonephritis. Similarly, mice (BALB/c) transgenic for a trimmed hlL-6 cDNA
driven by a mouse H-2Ld promoter randomly inserted into the genome display severe
cytosis (see, Suematsu et al. (1992) Generation of cytomas with the
chromosomal translocation t(12;15) in interleukin 6 transgenic mice, Proc. Natl.
Acad. Sci. USA -235). Although C57BL/6 mice that overexpress hlL-6 do not
develop transplantable plasmacytomas (they do exhibit plasmacytosis), transgenic
BL/6 mice back-crossed into BALB/c mice reportedly do.
Random transgenesis of a hlL-6 cDNA driven by a glial fibrillary acidic protein
(GFAP) gene er reportedly results in hlL-6 overexpression in the mouse
central nervous , which also leads to icant pathologies (see, Campbell et
al. (1993) Neurologic disease induced in transgenic mice by al overexpression
of interleukin 6, Proc. Natl. Acad. Sci. USA 90:10061-10065). These mice exhibit
ive neuropathology and reactive astrocytosis resulting from lL-6 expression in
the CNS due to loss of control as the result of random integration of an lL-6
transgene at an apparently CNS-permissive transcriptional locus. Although
expression of hlL-6 cDNA linked to a B-globin 3’-UTR and driven by a neuron-specific
e promoter microinjected into fertilized mouse eggs (F1 C57BL/6 x BALB/c)
produced mice with a normal lifespan and without apparent neurological defects that
expressed hlL-6 in neurons but not elsewhere (see, Fattor et al. (1994) lL-6
Expression in Neurons of Transgenic Mice Causes Reactive Astrocytosis and
Increase in Ramified Microglial Cells But No al Damage, Eur. J. Neuroscience
7:2441-2449), the mice exhibited high levels (20- to 30-fold higher than wild-type) of
activated and enlarged astrocytes with increased processes throughout the brain, as
well as a 10- to 15-fold increase in ramified microglial cells in white matter. Thus,
brain expression of IL-6 reportedly leads to conditions that range from ve
astrocytosis to frank and profound neuropathology.
Microinjection into fertilized eggs of an F1 cross of C57BL/6x”DBAII” mice of
a 639-bp hlL-6 cDNA linked to a B-globin 3’-UTR and a mouse MT-1 promoter
reportedly ed a transgenic mouse in which the hlL-6 gene was ly
integrated produced a weakened and diseased mouse that dies young of kidney
failure (see Fattori et al. (1994) Blood, pment of ssive Kidney Damage
and Myeloma Kidney in Interleukin-6 Transgenic Mice, Blood 63(9):2570-2579).
Transgenic mice expired at 12-20 weeks and exhibited elevated levels of a1 and [5-
globulins in plasma, hypergammaglobulinemia, elevated megakaryocytes in spleen
(3-fold higher than wild-type) and bone , plasmacytosis of lymphoid organs
(spleen, thymus, and lymph nodes) characterized by abnormal and compactly
arranged plasmocytoid cells, and glomerulonephritis leading to glomerulosclerosis
similar to multiple myeloma.
Microinjection into fertilized eggs of a C57BL/6J mouse of a H-2Ld-driven hlL-
6 cDNA caused ILdependent muscle wasting in mice, characterized in part by a
icantly lower gastrocnemius muscle weight in enic mice as compared to
weight-matched controls, a difference that was ameliorated by treatment with an IL-6
antagonist (see, Tsujinaka et al. (1996) Interleukin 6 or Antibody Inhibits
Muscle Atrophy and Modulates Proteolytic Systems in Interleukin 6 Transgenic Mice,
J. Clin. Invest. 244-249). At 12 weeks these mice displayed serum hlL-6 levels
of more than 600,000 pg/mL. The transgenic mice also had livers that weighed
about 1,242 mg, as compared to control livers that were about 862 mg. Transgenic
mice treated with IL-6 antagonist had livers that weighed about 888 mg. Muscle
cathepsins B and B+L were significantly higher (20-fold and 62-fold) in transgenic
mice than in controls, a phenomenon that was eliminated in transgenic mice treated
with an IL-6 antagonist. cathepsin B and L mRNAs were estimated to be about
277% and 257%, respectively, as compared with ype mice; the difference was
icantly d with IL-6 nist treatment.
Mice comprising a hlL-6 minigene driven by a mouse MHC class I H-
2Ld promoter and a hlL-6R minigene driven by a chicken B-actin promoter, and a
gp130 gene, ted pathologies typical of hlL-6 transgenic mice (e.g.,
hepergammaglobulinemia, splenomegaly, mesangial proliferative glomerulonephritis,
lung lymphoid infiltration) as well as ventricular hypertrophy (Hirota et al. (1995)
Continuous activation of gp130, a signal-transducing or component for
interleukin 6—related nes, causes myocardial hypertrophy in mice, Proc. Natl
Acad. Sci. USA 92:4862—4866). The ventricular hypertrophy is believed to be
mediated by a continuous activation of gp130 (Id.). The role of lL-6 is reportedly to
help strengthen the ne or complex and induce dimerization of gp130,
which is the signal transducing component responsible for transducing the lL-6 signal
(Paonessa et al. (1995) Two distinct and ndent sites on lL-6 trigger gp130
dimer formation and signalling, EMBO J. 14(9):1942—1951). The activated complex
is believed to be a r composed of two lL-6, each lL-6 bound to one lL-6Ra
and two gp130 (each lL-6 contains two independent gp130-binding sites) exhibiting a
2:2:2 stoichiometry, wherein the dimerization of gp130 causes activation of JAK—Tyk
ne kinases, phosphorylation of gp130 and STAT family transcription s and
other intracellular substrates (Id.; Stahl, N. (1994) Association and Activation of Jak-
Tyk Kinases by CNTF-LlF-OSM-lL-6 [5 Receptor Components, Science 263:92—95),
tent with a general model of cytokine receptor complex formation (see, Stahl,
N. and oulos, G. (1993) The Alphas, Betas, and Kinases of Cytokine
Receptor Complexes, Cell 74:587-590; Davis et al. (1993) LIFRB and gp130 as
Heterodimerizing Signal ucers of the Tripartite CNTF Receptor, Science
260:1805-1808; Murakami et al. (1993) lLlnduced Homodimerization ofgp130 and
Associated tion of a Tyrosine Kinase, Science 2601808—1810).
Mice transgenic for human le-6R driven by a rat PEP carboxykinase
promoter and human lL-6 driven by a mouse metallothionein-1 promoter are
reportedly markedly smaller that mice transgenic for human lL-6 alone or human le-
6R alone (Peters et al. (1997) Extramedullary Expansion of Hematopoietic Progenitor
Cells in |nterleukin(|L-)—6—le-6R Double Transgenic Mice, J. Exp. Med. 185(4):?55-
766), reflected in d body fat and d weight (20-25 g vs. 40 g). Double
transgenic mice reportedly also exhibit spleen (5-fold) and liver (2—fold) enlargement
as compared with reportedly normal organ weights for single transgenic mice,
apparently due to extramedullary proliferation of hematopoeitic cells of spleena and
liver but not bone marrow, as well as elevated megakaryocytes in spleen and
plasmacellular infiltrates in all parenchymal organs (Id.). Double transgenics also
exhibit livers with an increase of about 200- to about 300-fold in granulocytes,
macrophages, progenitor cells, and B cells as compared with single transgenics; in
contrast, lL-6 single enic mice exhibited lesser increases in macrophages (15-
fold) and B cells (45-fold) (Id.). The extraordinary findings are presumably due to
stimulation of growth and differentiation of hematopoietic progenitor cells by
ting gp130 signal transduction (Id.).
Further, double transgenic (mouse metallothionine promoter-driven
rat PEP ykinase promoter-driven hlL-6R) mice exhibit a hepatocellular
hyperplasia that is reportedly identical to human nodular regenerative lasia
with sustained hepatocyte proliferation that strongly suggests that |L-6 is responsible
for both hepatocyte proliferation and pathogenic hepatocellular transformation
(Maione et al. (1998) Coexrpession of |L-6 and soluble lL-6R causes nodular
regenerative hyperplasia and adenomas of the liver, EMBO J. 17(19):5588—5597).
Because hepatocellular hyperplasia is reportedly not observed in single transgenic
hlL-6 mice and hlL-6 can bind mlL-6R, the finding may appear paradoxical until it is
considered that the double transgenic may result in higher levels of hlL-6 complexed
to soluble |L-6R (here, soluble hlL-6R), which complex is a more potent inhibitor that
|L-6 alone (Id.).
] In contrast to mice that are transgenic for human |L-6, humanized |L-6
mice that comprise a replacement at an endogenous mouse |L-6 locus, which retain
mouse regulatory elements but comprise a humanization of |Lencoding sequence,
do not exhibit the severe ogies of prior art mice. Genetically modified mice that
were heterozygous or gous for hlL-6 were grossly normal.
Mice with a humanized lL-6 gene (MAID 760) as described in the
Examples were immunophenotyped and found to have normal B cell numbers in
FACS analyses (lymphocyte-gated) of spleen B cells using a pan B cell marker
R(B220)) (. For spleen, wild-type mice ted 63% B cells; hlL-6
heterozygote mice exhibited 63% B cells; and mice homozygous for hlL-6 at the
endogeous mouse locus ted 63% B cells. B cell numbers for homozygous hlL-
6 mice immunized with TNP-KLH were also normal (65% for wild-type, and 61% for
hlL-6 homozygotes).
Splenic T cells were also about the same as wild-type (.
tages of splenic T cells for Thelper/Tcytoxic were, for wild-type 20%/40%
(ratio of 1.4:1); for hlL-6 heterozygotes 23%/14% (ratio of 16:1); for hlL-6
homozygotes 21%/15% (ratio of 1.4:1) (markers were CD8a-APC; CD4-FITC).
gous hlL-6 mice immunized with TNP-KLH exhibited similar splenic T cell
numbers to wild-type mice, i.e., Thelper/Tcytotoxic were 22%/20% (ratio of 1.1:1) as
compared with 21 %/19% for wild-type (also a ratio of 1.1 :1 ).
Humanized |L-6 mice also ted about normal levels of splenic NK
cells on FACS analysis (CD11b and DX5) (. hlL-6 heterozygotes exhibited
2.2% NK cells, and hlL-6 homozygotes exhibited 1.8% NK cells, whereas wild-type
mice exhibited 2.4% NK cells. Following immunization with TN P-KLH, homozygotes
exhibited 1.6% splenic NK cells, s wild-type mice exhibited 2.1% splenic NK
cells.
zed |L-6 mice also exhibited normal levels of splenic
(Gr1) cells (. hlL-6 heterozygotes exhibited 7.0% GR1+ cells (1.3%
Gr1hi); homozygotes exhibited 6.8% Gr1+ cells (0.9% Gr1hi), whereas wild-type mice
ted 8.0% Gr1+ cells (1 .8%Gr1hi). zed |L-6 homozygotes (immunized
with TNP-KLH) exhibited 11% Gr1+ cells (4.0% Gr1hi), whereas wild-type mice
exhibited 10% Gr1+ cells (30% GM“).
Humanized |L-6 mice also exhibited normal blood B and T cell
numbers in FACS analysis (and . FACs with a pan B cell marker
R(B220)) revealed that homozygous hlL-6 mice ed 52% B cell as
compared with wild-type 53%; zygotes exhibited 38% (an average of two
ent stainings of 29% and 47%). Homozygous hlL-6 mice immunized with TNP-
KLH gave similar B cell numbers (43%, as compared with 45% for wild-type mice).
Humanized |L-6 mice exhibited normal blood T cell numbers in FACS
analysis as measured by CD8a and CD4 staining. Heterozygous hlL-6 mice
exhibited Thelper/Tcytotoxic numbers of 39%/26% (ratio of 1.5:1); homozygous hlL-
6 mice exhibited Th/Tc numbers of 24%/20% (ratio of 1.2:1), whereas wild-type mice
exhibited Th/Tc numbers of % (ratio of 1.3:1). Homozygous hlL-6 mice
immunized with TNP-KLH had Th/Tc numbers of 29%/21% (ratio of 1.4:1), whereas
wild-type immunized mice had Th/Tc numbers of 28%/23% (1 .2:1).
Humanized lL-6 mice also exhibited myeloid cell numbers in blood
that were similar to wild-type mice as measured by FACS analysis of naive and
immunized mouse blood stained with Ly6G/C(Gr1) and CD11b, as well as CD11b
and DX5 (, , and FIG 12). Heterozygous hlL-6 mice exhibited %Gr+
cells of 10.8%, homozygotes 6.9%, whereas wild-type mice exhibited 9.7%.
Immunized hlL-6 homozygotes exhibited M1(Ly6G/C(Gr) of 101-104)/
G/C(Gr) staining of about 102-103) numbers of 43%/34%, whereas ype
mice had numbers of 45%/38%. FACS plots of CD11b (vertical axis) vs. Ly6G/C
(horizontal axis) for immunized homozygous hlL-6 mice showed cell percentage in
quadrants (upper left/upper right/lower right) of 16%/8%/3%, which were identical to
immunized ype quadrant numbers.
Homozygous TNP-KLH-immunized humanized IL-6 mice exhibited
CD11b vs. DX5(NK) staining FACS plots that were similar to immunized wild-type
mice. Quadrant analysis blood FACS plots (CD11b vertical axis, DX5(NK) horizontal
axis) revealed upper left/upper lower right numbers of 9.5%/17%/10% for hlL-6
homozygotes and 6.5%/17.3%/14% for wild-type mice.
Humanized IL-6 mice exhibited an isotype response that was
essentially the same as observed in wild-type mice. Early and final lgG1, IgG2a,
IgG2b, IgG3, lgA, IgE, and IgM levels were about the same as observed in wild-type
mice. In one experiment, final IgM was slightly higher in humanized mice; final lgG3
was also elevated in humanized mice.
B cell development in naive hlL-6 mice was essentially
indistinguishable from development in wild-type mice based on FACS analysis of
bone marrow lgM/CD24/B220 staining (). lmmunophenotyping of immune
mice ed that marker populations for various cell types in the B cell
development ssion were ially normal in hlL-6 mice. Progression of cells
from hematopoietic stem cells, common lymphoid itors, ProB cells, PreB cells,
and immature and mature B cells is normal in hlL-6 mice ( and )
EXAMPLES
Example 1: Replacement of Endogenous Mouse lL-6 Gene with hlL-6 Gene
The 4.8-kb human IL-6 gene containing exons 1 through 4 of the
human IL-6 gene ed 6.8 kb of the murine IL-6 gene locus.
A targeting construct for replacing the mouse with the human IL-6
gene in a single targeting step was constructed using VELOCIGENE® genetic
engineering logy (see, Valenzuela et al. (2003) High-throughput engineering
of the mouse genome d with high-resolution expression analysis, Nature
Biotech, 21(6):652-659). Mouse and human IL-6 DNA were obtained from bacterial
artificial some (BAC) RPCI-23 clone 368C3, and from BAC CTD clone
2369M23, respectively. Briefly, a Notl linearized targeting construct generated by
gap repair cloning containing mouse IL-6 upstream and downstream homology arms
flanking a 4.8 kb human IL-6 ce extending from ATG in exon 1 to exon 5 with
16 nucleotides of 3’ downstream sequence (genomic nates: NCBIh37.1:
,766,882 to 22,771,637) and a floxed neo selection cassette, was
electroporated into F1 H4 mouse embryonic stem (ES) cells (C57BL/6 x 129 F1
hybrid). Correctly targeted ES cells (MAID 790) were further electroporated with a
transient Cre-expressing vector to remove the drug ion cassette. Targeted ES
2012/062379
cell clones without drug cassette (MAID 1428) were introduced into an 8-cell stage
mouse embryo by the VELOCIMOUSE® method (see, US Pat. No. 7,294,754,
7,576,259, 7,659,442, and Poueymirou et al. (2007) F0 generation mice that are
essentially fully derived from the donor gene-targeted ES cells allowing immediate
phenotypic analyses Nature Biotech. 25(1):91-99). VELOCIMICE® (F0 mice fully
derived from the donor ES cell) bearing the humanized IL-6 gene were identified by
ping for loss of mouse allele and gain of human allele using a cation of
allele assay (see, Valenzuela et al. ).
] Correctly targeted ES cell clones were identified by a Ioss-of—native-
allele (LONA) assay (Valenzuela et al. 2003) in which the number of copies of the
native, unmodified [[6 gene were determined by two TaqManTM quantitative
polymerase chain reactions (qPCRs) specific for sequences in the mouse ”6 gene
that were targeted for deletion. The qPCR assays comprised the following primer-
probe sets (written 5’ to 3’): upstream fonNard primer, TTGCCGGTTT TCCCTTTTCT
C (SEQ ID NO:1); upstream reverse primer, GGCC GTGGTTGTC (SEQ ID
NO:2); upstream probe, FAM-CCAGCATCAG TCCCAAGAAG GCAACT-BHQ (SEQ
ID NO:3); ream forward primer, TCAGAGTGTG GGCGAACAAA G (SEQ ID
NO:4); downstream reverse primer, GTGGCAAAAG CAGCCTTAGC (SEQ ID NO:5);
ream probe, FAM-TCATTCCAGG CCCTTCTTAT TGCATCTG-BHQ (SEQ ID
NO:6); in which FAM refers to the 5-carboxyfluorescein fluorescent probe and BHQ
refers to the fluorescence quencher of the black hole quencher type (Biosearch
Technologies). DNA purified from ES cell clones that that have taken up the targeting
vector and incorporated in their genomes was combined with TaqManTM Gene
Expression Master Mix (Life Technologies) according to the manufacturer’s
suggestions in a ll PCR plate (MicroAmpTM Optical 384-Well Reaction Plate,
Life Technologies) and cycled in an d Biosystems Prism 7900HT, which
collects fluorescence data during the course of the PCRs and determines a threshold
cycle (Ct), the fractional PCR cycle at which the accumulated fluorescence reaches a
pre-set threshold. The upstream and downstream l/6-specific qPCRs and two qPCRs
for non-targeted nce genes were run for each DNA . The differences in
the Ct values (ACt) between each l/6-specific qPCR and each reference gene qPCR
were calculated, and then the difference between each ACt and the median ACt for
all samples assayed was calculated to obtain AACt values for each sample. The copy
number of the ”6 gene in each sample was calculated from the following formula:
copy number = 2 . 2-AACt. A correctly targeted clone, having lost one of its native
, will has an ”6 gene copy number equal to one. Confirmation that the human
IL6 gene ce replaced the deleted mouse II6 gene sequence in the humanized
allele was confirmed by a TaqManTM qPCR assay that comprises the following
primer-probe sets (written 5’ to 3’): the human fonNard primer,
TCCACTGGAATTTG (SEQ ID NO:7); the human reverse primer,
GTTCAACCACAGCCAGGAAAG (SEQ ID NO:8); and the human probe, FAM-
AGCTACAACTCATTGGCATCCTGGCAA-BHQ (SEQ ID NO:9).
] The same LONA assay was used to assay DNA purified from tail
biopsies for mice derived from the targeted ES cells to determine their II6 genotypes
and m that the humanized II6 allele had transmitted through the ne. Two
pups heterozygous for the replacement are bred to generate a mouse that is
homozygous for the replacement of the endogenous mouse lL-6 gene by the human
IL-6 gene. Pups that are homozygous for the replacement are used for phenotyping.
The am junction of the murine locus and the sequence
containing the hlL-6 gene is designed to be within 5’-AATTAGAGAG CCTA
ATAAATATGA GACTGGGGAT GTCTGTAGCT CATTCTGCTC TGGAGCCCAC
CAAGAACGAT AGTCAATTCC AGAAACCGCT ATGAACTCCT CAAG
TAAGTGCAGG AAATCCTTAG CCCTGGAACT GCCAGCGGCG GTCGAGCCCT
GTGTGAGGGA GGGGTGTGTG GCCCAGG (SEQ ID NO:10), wherein the final
mouse nucleotide priorto the first nucleotide of the human gene is the “T” in CCGCT,
and the first nucleotide of the human sequence is the first “A” in ATGAA. The
downstream junction of the sequence containing the hlL-6 gene and the murine locus
is designed to be within 5’-TTTTAAAGAA ATATTTATAT TGTATTTATA
TAATGTATAA ATGGTTTTTA TACCAATAAA TGGCATTTTA AAAAATTCAG
CAACTTTGAG ACGC TCCCGGGCTC GATAACTATA ACGGTCCTAA
GGTAGCGACT CGAGATAACT T-3’ (SEQ ID NO:11), wherein the final nucleotide of
the human sequence is with the final “G” in TCACG and the first nucleotide of the
mouse sequence is the first “C” in CTCCC; the downstream junction region also
contained a onP site at the 3’ end (the beginning of which is shown) for removal of a
floxed ubiquitin promoter-driven neo cassette. The junction of the neo cassette with
the mouse lL-6 locus is designed to be within 5’-TATACGAAGT TATCCTAGGT
TGGAGCTCCT AAGTTACATC CAAACATCCT CCCCCAAATC TAAG
CACTTTTTAT GACATGTAAA GTTAAATAAG AAGTGAAAGC TGCAGATGGT
GAGTGAGA (SEQ ID , where the final “C” of AGCTC is the final nucleotide of
the neo te; the first nucleotide of the mouse genome ing the cassette is
the initial “C” of CTAAG.
Example 2: phenotyping of Naive and lmmunized hlL-6 Mice: B Cells
Mice homozygous for the h|L-6 gene replacement were analyzed for B
cells (DC445R(B220). Lymphocyte-gated fractions from spleen cell preparations of
naive and immunized LH) h|L-6 mice were stained and immunophenotyped
using flow cytometry. FACS analysis showed that the percentage of B cells of the
spleen cell preparation as measured by CD45R(8220)-FITC staining were about the
same (63% of cells) for preparations from naive ype, hlL-6 heterozygotes, and
hlL-6 homozygotes. For immunized mice, B cells accounted for about 65% of total
cells of the spleen cell preparation in wild-type mice, and about 61% of total cells in
h|L-6 gotes. Spleens of h|L-6 mice (both naive and immunized) contain a
population of B cells that is about the same size as the splenic B cell population in
wild-type mice.
Bone marrow of wild-type, h|L-6 heterozygotes, and h|L-6
homozygotes was stained with B cell markers (CD45R(B220)-APC, CD24(HSA)-PE,
or CD43 conjugated to a dye and/or lgM (lgM-FITC). B cell development in bone
marrow of normal mice will be ted in e markers as cells progress from
stem cells to early pro-B cells to late pro-B cells, to large pre-B cells to small pre-B
cells to re B cells and finally, to mature B cells. Common lymphocyte
progenitor pro-B cells will express CD45R, and in later stages will s lgM as
immature and later as mature B cells. Thus, CD45R-stained and anti-lgM-stained B
cells should reveal a pattern characteristic of B cell development. Bone marrow of
h|L-6 heterozygotes and homozygotes displayed a pattern of CD45R(8220)-APC
and anit-lgM-FITC staining that was ially indistinguishable from wild-type bone
marrow, showing populations of B cells that stained positive for CD45R(B220) and
lgM, or CD45R(B220) alone. B cell sub-populations in bone marrow of h|L-6 mice
revealed by FACS staining were similar to those in wild-type mice (Table 1; see also,
).
Table 1. B Cells in Bone Marrow of Naive Mice
hlL-6 Mouse
Wild-type Mouse
(%) Heterozygote Homozygote
(%) (%)
CLP-ProB
PreB-lmmatureB
] ng for CD24 (see ) revealed the (normal) pattern shown
in Table 2, indicating normal development in bone marrow.
Table 2. B Cells in Bone Marrow of Naive Mice
hlL-6 Mouse
Wild-type Mouse_
(0/0) Heterozygote Homozygote
(%) (%)
Developing HSC-
46.6 46 43
Mature CLP/early
-2 9-0 10-1
ProB
Late ProB, PreB,
7-2 11.6 10-7
Immature B
Mature B 14.1 14.9 17
ng for CD43 (see ) revealed the (normal) pattern shown
in Table 3, indicating normal development in bone marrow.
Table 3. B Cells in Bone Marrow of Naive Mice
hlL-6 Mouse
Wild-type Mouse
(°/o) Heterozygote Homozygote
(%) (%)
PreBll-lmmature
28.4 21.4 21.2
B cells
Mature B cells 8.1
Thus, immunophenotyping of nai've hlL-6 mice revealed that B cell
development in such mice is essentially .
Example 3: Replacement of nous Mouse lL-6Ra Ectodomain Gene
Sequence with hlL-6Rq Ectodomain Gene Sequence
The 45 kb human lL-6Ra gene containing exons 1 through 8 of the
human lL-6Ra gene replaced 35.4 kb of the murine lL-6Rq gene locus. Mouse
exons 9 and 10 were retained; only exons 1-8 were humanized. In total, 35,384 nt of
mouse sequence was replaced by 45,047 nt of human sequence.
A targeting construct for replacing the mouse with the human lL-6Rd
gene in a single targeting step was constructed using VELOCIGENE® c
engineering technology (see, Valenzuela et al. (2003) High-throughput engineering
of the mouse genome coupled with high-resolution expression analysis, Nature
Biotech, 21(6):652-659). Mouse and human lL-6Rq DNA were ed from
bacterial artificial chromosome (BAC) RPCl-23 clone 125J8, and from BAC CTD
clone 2192J23, respectively. Briefly, a Notl linearized targeting construct generated
by gap repair cloning containing mouse lL-6Rq upstream and downstream homology
arms flanking a 45 kb human lL-6Rq sequence extending from ATG in exon 1 to
exon 8 with 69 nucleotides of 3’ downstream sequence and a floxed neo selection
cassette, was electroporated into F1H4 mouse embryonic stem (ES) cells (C57BL/6
x 129 F1 hybrid). Correctly targeted ES cells (MAID 794) were further electroporated
with a transient Cre-expressing vector to remove the drug selection te.
Targeted ES cell clones t drug cassette (MAID 1442) were introduced into an
8-cell stage mouse embryo by the VELOCIMOUSE® method (see, US Pat. No.
7,294,754, 259, 7,659,442, and Poueymirou et al. (2007) F0 generation mice
that are essentially fully derived from the donor gene-targeted ES cells allowing
immediate phenotypic analyses Nature h. 25(1):91-99). VELOCIMICE® (F0
mice fully derived from the donor ES cell) bearing the humanized lL-6Rq gene were
identified by genotyping for loss of mouse allele and gain of human allele using a
modification of allele assay (see, Valenzuela et al. (2003)).
Correctly targeted ES cell clones were identified by a Ioss-of—native-
allele (LONA) assay (Valenzuela et al. 2003) in which the number of copies of the
native, unmodified ”6 gene were determined by two TaqManTM quantitative
polymerase chain reactions (qPCRs) specific for sequences in the mouse ”6 gene
that were targeted for deletion. The qPCR assays comprised the following -
probe sets (written 5’ to 3’): upstream forward , GCCCTAGCAT GCAGAATGC
(SEQ ID NO:13); upstream reverse primer, TCCC ACATCCTTTG C (SEQ
ID NO:14); upstream probe, TCCA TCCT GTGAG (SEQ ID
NO:15); downstream forward primer, GAGCTTGCCC CCAGAAAGG (SEQ ID
NO:16); downstream reverse primer, CGGCCACATC AGAC (SEQ ID
NO:17); downstream probe, CATGCACTGC CCCAAGTCTG GTTTCAGT (SEQ ID
NO:18). DNA ed from ES cell clones that that have taken up the targeting vector
and incorporated in their genomes was combined with TaqManTM Gene Expression
Master Mix (Life Technologies) according to the cturer’s suggestions in a
384-well PCR plate (MicroAmpTM Optical 384-Well Reaction Plate, Life
Technologies) and cycled in an Applied Biosystems Prism 7900HT, which collects
fluorescence data during the course of the PCRs and ines a old cycle
(Ct), the fractional PCR cycle at which the accumulated fluorescence reaches a pre-
set threshold. The upstream and downstream lL-6Rq-specific qPCRs and two
qPCRs for non-targeted reference genes were run for each DNA sample. The
differences in the Ct values (ACt) between each IL-6Rq-specific qPCR and each
reference gene qPCR were ated, and then the difference between each ACt
and the median ACt for all samples assayed was calculated to obtain AACt values for
each sample. The copy number of the ”6 gene in each sample was ated from
the following formula: copy number = 2 - 2-AACt. A correctly ed clone, having
lost one of its native copies, will have an IL-6Rq gene copy number equal to one.
Confirmation that the human IL-6Ra gene sequence replaced the deleted mouse IL-
6Rq gene sequence in the humanized allele was med by a TaqManTM qPCR
assay that comprises the following primer-probe sets (written 5’ to 3’): the human
fonNard primer, GGAGAGGGCA GAGGCACTTA C (SEQ ID NO:19); the human
reverse , GGCCAGAGCC CAAGAAAAG (SEQ ID N020); and the human
probe, CCCGTTGACT GTAATCTGCC CCTGG (SEQ ID NO:21).
The same LONA assay was used to assay DNA purified from tail
biopsies for mice derived from the targeted ES cells to determine their IL-6Ra
genotypes and confirm that the humanized IL-6Rq allele had itted through the
germline. Pups heterozygous for the replacement are bred to generate a mouse that
is gous for the replacement of the endogenous mouse IL-6Rq gene by the
human IL-6Ra (ectodomain) gene. Pups that are homozygous for the replacement
are used for phenotyping.
The upstream junction of the murine locus and the sequence
containing the hlL-6Rq gene is designed to be within 5’-CGAGGGCGAC
TGCTCTCGCT GCCCCAGTCT GCCGGCCGCC CGGCCCCGGC TGCGGAGCCG
CTCTGCCGCC CGCCGTCCCG CGTAGAAGGA AGCATGCTGG CCGTCGGCTG
CGCGCTGCTG GCTGCCCTGC TGGCCGCGCC GGGAGCGGCG CTGGCCCCAA
GGCGCTGCCC TGCGCAGGGT AAGGGCTTCG G (SEQ ID NO:22), wherein the
final mouse nucleotide prior to the first nucleotide of the human gene is the “C” in
GAAGC, and the first nucleotide of the human sequence is the first “A” in ATGCT.
The downstream junction of the sequence containing the hlL-6 gene and the murine
locus is designed to be within 5’-CAAGATTATT GGAGTCTGAA ATGGAATACC
TGTTGAGGGA AATCTTTATT GCCC TCAA TGCTTTTGAT
TCCCTATCCC TGCAAGACCC GGGCTCGATA ACTATAACGG TCCTAAGGTA
CGAG ATAACTTC-3’ (SEQ ID NO:23), wherein the final nucleotide of the
human sequence is with the final “A” in CAAGA and the first nucleotide of the mouse
ce is the first “C” in CCCGG; the downstream junction region also contained a
onP site at the 3’ end for removal of a floxed ubiquitin promoter-driven neo cassette.
The first nucleotide of the loxp site is the first "A" in ATAAC. The junction of the neo
cassette with the mouse IL-6Ra locus is designed to be within 5'-TATACGAAGT
TATCCTAGGT TCTA CTCCATATGC TCACTTGCCG GCTA
CGATACGGTG AGGCCCGTGC GAAGAGTGGC ACAGATCAGG AGGCTTATGT
GGTCAGTCCA CAGTATGGC (SEQ ID NO:24), where the final "C" of AGCTC is the
final nucleotide of the neo cassette; the first nucleotide of the mouse genome
following the cassette is the initial “T” of TACTC.
Where the terms “comprise”, “comprises”, “comprised” or “comprising” are used
in this ication (including the claims) they are to be interpreted as ying the
presence of the stated features, integers, steps or components, but not precluding the
presence of one or more other features, integers, steps or components, or group thereof.
The discussion of documents, acts, materials, devices, articles and the like is
ed in this specification solely for the purpose of providing a context for the present
invention. It is not suggested or represented that any or all of these matters formed part of
the prior art base or were common general knowledge in the field relevant to the present
invention as it d before the priority date of each claim of this application.
Claims (18)
1. A genetically modified mouse comprising a replacement at an endogenous mouse IL- 6 locus of a mouse gene encoding IL-6 with a human gene encoding human IL-6, wherein the human gene encoding human IL-6 is under control of endogenous mouse regulatory ts at the endogenous mouse IL-6 locus.
2. The genetically modified mouse of claim 1, wherein the human gene encoding human IL-6 ses exons 1 h 5 of the human IL-6 gene of the CTD-2369M23 bacterial artificial chromosome.
3. The genetically modified mouse of claim 1, wherein the mouse expresses a mouse IL-6Rα.
4. The genetically modified mouse of claim 1, wherein the mouse expresses a humanized IL-6Rα wherein the endogenous mouse IL-6Rα gene has been replaced with a human sequence comprising a sequence that encodes an main of a human .
5. The genetically modified mouse of claim 1, n the mouse does not exhibit a feature selected from plasmocytosis, glomerulosclerosis, glomerulonephritis, kidney failure, hypergammaglobulinemia, elevated megakaryocytes in spleen, elevated megakaryocytes in bone marrow, splenomegaly, lymph node ement, compacted abnormal plasma cells, and a combination thereof.
6. The genetically modified mouse of claim 4, wherein the humanized IL-6Rα comprises a human ectodomain.
7. The genetically modified mouse of claim 6, wherein the humanized IL-6Rα comprises a mouse transmembrane domain and a mouse cytoplasmic domain.
8. The genetically modified mouse of claim 1, wherein the mouse ses a cell that expresses an IL-6Rα that comprises a human ectodomain on the surface of the cell.
9. A genetically modified mouse, comprising a humanization of an endogenous mouse IL-6Rα gene, wherein the zation comprises a replacement of a mouse IL-6Rα ectodomain-encoding sequence with a human IL-6Rα ectodomain-encoding sequence at the nous mouse IL-6Rα locus, and wherein the humanized IL-6Rα gene is under control of endogenous mouse regulatory elements.
10. The genetically modified mouse of claim 9, wherein a contiguous mouse sequence comprising mouse exons 1 through 8 is replaced with a contiguous genomic fragment of human IL-6Rα ce encoding a human IL-6Rα ectodomain.
11. The genetically modified mouse of claim 10, wherein the contiguous genomic fragment of human IL-6Rα sequence encoding the ectodomain is found in the CTD-2192J23 bacterial artificial chromosome.
12. The genetically modified mouse of claim 9, r sing a humanized IL-6 gene comprising a replacement at an endogenous mouse IL-6 locus of a mouse gene encoding IL-6 with a human gene encoding human IL-6.
13. The genetically modified mouse of claim 12, wherein the humanized IL-6 gene is under control of nous mouse regulatory elements.
14. A method for making a humanized mouse, comprising replacing a mouse gene sequence ng mouse IL-6 with a human gene encoding human IL-6 so that the human IL-6 gene is under control of endogenous mouse tory elements.
15. A method for making a humanized mouse, comprising replacing all mouse exons encoding ectodomain sequences of mouse IL-6Rα with a human genomic fragment encoding human IL-6Rα ectodomain to form a humanized IL-6Rα gene, wherein the humanized IL-6Rα gene is under control of endogenous mouse regulatory elements.
16. A cally modified mouse comprising a humanized IL-6Rα gene comprising a replacement of mouse ectodomain-encoding sequence with human ectodomain ce, n the humanized IL-6Rα gene comprises a mouse transmembrane sequence and a mouse cytoplasmic sequence; wherein the mouse further comprises a gene encoding a human IL-6, n the genes encoding human IL-6 and humanized IL-6Rα are under control of endogenous mouse regulatory elements.
17. The genetically modified mouse of claim 16, wherein the mouse does not express a mouse IL-6Rα and does not express a mouse IL-6.
18. The genetically modified mouse according to claim 1, 9 or 16, or the method according to claim 14 or 15, substantially as herein described with nce to the Examples and/or
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ709432A NZ709432B2 (en) | 2011-10-28 | 2012-10-29 | Humanized il-6 and il-6 receptor |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552900P | 2011-10-28 | 2011-10-28 | |
US61/552,900 | 2011-10-28 | ||
US201161556579P | 2011-11-07 | 2011-11-07 | |
US61/556,579 | 2011-11-07 | ||
PCT/US2012/062379 WO2013063556A1 (en) | 2011-10-28 | 2012-10-29 | Humanized il-6 and il-6 receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623145A NZ623145A (en) | 2015-09-25 |
NZ623145B2 true NZ623145B2 (en) | 2016-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11102962B2 (en) | Humanized IL-6 and IL-6 receptor | |
AU2012327206B2 (en) | Humanized IL-6 and IL-6 receptor | |
NZ623145B2 (en) | Humanized il-6 and il-6 receptor | |
NZ709432B2 (en) | Humanized il-6 and il-6 receptor |